Vasculotide can attenuate the immune inflammatory response and airway remodeling in chronic experimentally-induced airway inflammation in mice

Abstract Inflammation and airway remodeling are features associated with chronic asthmatic lungs. Previous reports have shown the benefits of the angiopoietin-1/Tie2 signaling axis on acute experimentally-induced asthma in mice. However, the more chronic effects as well as the interaction between the inflammatory and vascular components is poorly. Thus, we evaluated the impact of vasculotide, a synthetic Tie2 agonist in a chronic model of asthma. During the chronic allergic response in mice, we show that in addition to endothelial Tie2 receptor expression, there is an increased proportion of dendritic cells and monocytes expressing Tie2. Treatment of experimentally-induced chronic airway inflammation in mice with vasculotide correlated with a skewed CD4+ TH subsets and cytokine profile in the bronchoalveolar lavage of animals. This modified cytokine milieu promoted an altered endothelial cell response characterized by reduced expression of CD62E, CD54 and CD106 on endothelial cells, decreased cellular migration of inflammatory cells to the lung as well as reduced mucus accumulation. Analysis of lung tissues of animals treated with vasculotide revealed a decrease in collagen deposition and thinning of the smooth muscle cell layer in the airways of mice with chronic allergic airway inflammation. Our results demonstrate that vasculotide can impact the inflammatory and remodeling components in chronic asthma through its action on both cells of the immune response and on endothelial cells.